Table 2 General characteristics, comorbidity and corticosteroids treatment in NCAP and CAP control groups according to macrolide containing regimens and non-macrolide regimens
From: Lung inflammatory pattern and antibiotic treatment in pneumonia
NCAP | CAP controls | |||||
|---|---|---|---|---|---|---|
Macrolide regimens α | Non-macrolide regimen β | p value* | Macrolide regimens α | Non-macrolide regimens β | p value* | |
Subjects, n | 23 | 29 | 9 | 6 | ||
Age, years | 60 ± 4 | 63 ± 3 | NS | 78 ± 3 | 70 ± 9 | NS |
Male/Female | 12/11 | 19/10 | NS | 7/2 | 5/1 | NS |
Co-morbidity, n | ||||||
- Cerebrovascular disease | 4(17) | 7(24) | NS | 3(33) | 0 | NS |
- Heart disease | 4(17) | 8(28) | NS | 2(22) | 1(17) | NS |
- COPD | 1(4) | 6(21) | NS | 3(33) | 4(67) | NS |
Risk class of Fine | NS | NS | ||||
I-II | 7(30) | 6(21) | 0 | 1(17) | ||
III-V | 16(70) | 23(79) | 9(100) | 5(83) | ||
Inhaled corticosteroid | 0 | 2(7) | NS | 1(11) | 0 | NS |
Systemic corticosteroid | 3(13) | 6(21) | NS | 4(44) | 2(33) | NS |